PEN
Penumbra Inc
NYSE · Healthcare · Medical - Devices · US
$322.45
+0.76%Year over year
Reported trailing growth
- Revenue
- +17.0%
- EBITDA
- +12.1%
- EBIT
- +9.5%
- EPS
- -5.9%
- Free cash flow
- +31.2%
- Operating cash flow
- +28.4%
Forward estimates
Based on analyst estimates
- Revenue
- +12.5%
- EBITDA
- +38.5%
- EPS
- +45.7%
Three-year CAGR
- Revenue
- +18.3%
- EBITDA
- +95.5%
- EBIT
- +214.5%
- Net income
- +39.8%
- EPS
- +38.9%
- Free cash flow
- +46.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026